Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01359007 · ClinicalTrials.gov registry record · Phase 2
FOLFIRINOX in Patients With Inoperable Pancreatic Cancer
A Phase 2 study, sponsored by University of Oklahoma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01359007: Clinical Trial Phase 2 study, sponsored by University of Oklahoma.
NCT01359007 is a Phase 2 study that was terminated before completion, run by University of Oklahoma. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01359007, a Phase 2 study, was terminated before completion, sponsored by University of Oklahoma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The prognosis of patients with locally advanced unresectable pancreatic cancer is poor, and the median survival is less than 1 year. FOLFIRINOX therapy, which induces tumor downstaging sufficient to allow surgical resection, could improve the overall survival of patients with locally advanced pancreatic cancer. Based on the FOLFIRINOX regimen for advanced pancreatic cancer, a phase II study of this regimen in patients with locally advanced unresectable and borderline pancreatic cancer is planned to determine the rate of conversion to operability.
Interventions
- DRUG Irinotecan, Oxaliplatin, Leucovorin, 5-FU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Why NCT01359007 stopped before completion
NCT01359007 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Irinotecan, Oxaliplatin, Leucovorin, 5-FU is the first listed.
NCT01359007 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01359007 about?
NCT01359007 is a clinical study titled "FOLFIRINOX in Patients With Inoperable Pancreatic Cancer". The prognosis of patients with locally advanced unresectable pancreatic cancer is poor, and the median survival is less than 1 year. FOLFIRINOX therapy, which induces tumor downstaging sufficient to allow surgical resection, could improve the overall survival of patients with locally advanced pancre...
What is the current status of trial NCT01359007?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2011-05. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01359007?
The interventions under investigation include: Irinotecan, Oxaliplatin, Leucovorin, 5-FU (DRUG).
Who is sponsoring clinical trial NCT01359007?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01359007's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia